HENGRUI PHARMA (01276.HK): hetrombopag NDA accepted in China
- The NMPA accepted the new-indication filing under acceptance number CXHS2600158 at the marketing stage.
- The indication covers chronic liver disease-associated thrombocytopenia in adults before elective invasive procedures.
NewTimeSpace News: On 20 November 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 01276) said in an overseas regulatory announcement under Rule 13.10B that the NMPA had accepted its marketing application for a new indication of hetrombopag olamine tablets, under acceptance number CXHS2600158. The proposed indication is chronic liver disease-associated thrombocytopenia in adults scheduled for elective invasive procedures, including diagnostic ones.
The filing rests on a multicentre, randomised, double-blind, placebo-controlled Phase III trial (SHR8735-302) led by Professor Zhou Jian of Zhongshan Hospital, Fudan University, with 21 mainland sites and 127 patients; the primary endpoint was met in August 2026, with the treatment arm significantly better and safety favourable. Comparable products sold about USD 2.222 billion globally in 2025, and cumulative R&D spending was about RMB 668.2 million (unaudited).
- HENGRUI PHARMA (01276.HK): Five Drugs Get Clinical Trial Nod
- HENGRUI PHARMA (01276.HK): Six Drugs Cleared for Clinical Trials, Including Two ADCs
- HENGRUI PHARMA (01276.HK) gets clinical trial approvals for HRS-5346 tablets and SHR-1139 injection
- HENGRUI PHARMA (01276.HK): two drugs get clinical trial approval
- HENGRUI PHARMA (01276.HK): ADC filing accepted for priority review